Loading stock data…
ANIK
$14.85+2.40 (+19.28%)
Market ClosedLast close May 1
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anika Therapeutics, Inc. in the Healthcare sector is trading at $14.85. The stock is currently near its 52-week high of $16.24, remaining 38.8% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why ANIK maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.85
Potential Upside
5%
Whystock Fair Value$15.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Or...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$224.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.26%
Volume
Today's trading volume
232,473
Recent News
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Anika Therapeutics, Inc.'s Q1 2026 earnings call
Anika Therapeutics Q1 Earnings Call Highlights
Anika Therapeutics (NASDAQ:ANIK) reported first-quarter 2026 results highlighting continued momentum in its commercial channel, progress in its hyaluronic acid (HA)-based product pipeline, and early benefits from operational changes aimed at improving profitability and scalability. Commercial chann
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a differentiated hyaluronic acid-based technology platform,
Anika Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Anika Therapeutics, Inc.'s Q4 2025 earnings call